Drugs / A2MRP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06329492 | Jan 2024 → Jan 2026 | osteoarthritis, knee | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A2MRP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06329492 ↗ |
| Known as | Autologous Alpha-2 Macroglobulin Rich Plasma | “Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) is produced by filtering Platelet Poor Plasma (PPP), a Platelet Rich Plasma byproduct, through a hemoconcentrator filter.” NCT06329492 ↗ |
| Route | Other | “injection into the knee joint” NCT06329492 ↗ |